Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen: No Proof Apotex Biosimilar Approval Looming

This article was originally published in Scrip

Executive Summary

There's no need to expedite Apotex Inc.'s appeal of a Florida district court's decision to impose a preliminary injunction (PI) on the firm preventing it from marketing its pegfilgrastim biosimilar for 180 days after FDA approval because there's no evidence the agency's verdict on the product is looming, Amgen Inc. said in court documents filed on Dec. 18.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts